Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Beam Therapeutics Inc (NQ: BEAM ) 23.50 +0.09 (+0.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Beam Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Beam Therapeutics Via GlobeNewswire 2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street December 27, 2023 Wall Street is uber-bullish on these two Ark Invest holdings. Via The Motley Fool CRISPR Therapeutics sets sights on gene-editing cures for disease December 27, 2023 On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for Via MarketBeat Exposures Product Safety Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors December 14, 2023 From Beam Therapeutics Via GlobeNewswire Is Beam Therapeutics Stock a Buy Now? November 18, 2023 It has plenty of money, but it'll be facing plenty of competition, too. Via The Motley Fool Beam Therapeutics: Q3 Earnings Insights November 08, 2023 Via Benzinga Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? October 25, 2023 Beam Therapeutics' pipeline will look slimmer going forward. Via The Motley Fool Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday December 08, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. December 04, 2023 The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. Via The Motley Fool Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception November 29, 2023 The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. Via Benzinga Topics ETFs The 3 Best Gene Editing Stocks on the Frontier of Medicine November 20, 2023 Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. Via InvestorPlace 3 Monster Stocks in the Making November 18, 2023 These stocks could grow much larger over the next few years. Via The Motley Fool Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks November 14, 2023 You might not get a better chance to invest in these disruptive companies. Via The Motley Fool Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session November 13, 2023 Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. Via Benzinga Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results November 08, 2023 From Beam Therapeutics Via GlobeNewswire Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference November 08, 2023 From Beam Therapeutics Via GlobeNewswire Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners November 06, 2023 Roku vaulted 50% to become Ark Innovation's top holding. Via Investor's Business Daily 2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now November 05, 2023 These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. Via The Motley Fool Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On November 01, 2023 Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. Via InvestorPlace Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today October 31, 2023 Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology. Via The Motley Fool Verve Stock Soars On $250 Million Eli Lilly Deal October 31, 2023 Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs. Via Investor's Business Daily Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday October 31, 2023 U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session October 31, 2023 Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... Via Benzinga Topics Intellectual Property Exposures Intellectual Property After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? October 31, 2023 Some of the strategic shifts proposed by management are for the better. Via The Motley Fool Why Beam Therapeutics Stock Is Getting Bought Today October 31, 2023 Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's Via Benzinga Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease October 31, 2023 Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 From Beam Therapeutics Via GlobeNewswire Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender October 30, 2023 Via Benzinga Topics Earnings Exposures Financial 5 Reasons Beam Therapeutics Remains a Risky Stock October 30, 2023 Shares of the gene-editing biotech might not have hit rock bottom yet. Via The Motley Fool Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT October 25, 2023 From Beam Therapeutics Via GlobeNewswire Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session October 23, 2023 U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.